GRAND PHARMA (00512) surged over 3% intraday, with gains of 2.59% at the time of writing, trading at HK$8.32 and recording a turnover of HK$33.37 million. The company recently announced that its innovative traditional Chinese medicine drug GPN01360, developed for treating depression, has successfully met the clinical endpoint in its Phase II trial in China.
GPN01360 is a Class 1.1 innovative traditional Chinese medicine for treating depression (liver stagnation and spleen deficiency syndrome). Derived from the ancient classical prescription "Xiaoyao San," it has been optimized through modern pharmacological and clinical research. The formula consists of 12 herbal ingredients, including Bupleurum, Curcuma, and Bergamot, and is designed to soothe the liver, strengthen the spleen, relieve depression, and calm the mind.
GRAND PHARMA stated that the positive clinical trial data lays a solid foundation for further development of GPN01360. The drug is expected to address the challenge of poor patient compliance caused by side effects of existing Western medications, thereby improving long-term treatment adherence and efficacy. It may also offer a new solution to enhance clinical remission rates for depression.
Additionally, GPN01360 will provide robust evidence-based medical support for the use of traditional Chinese medicine in treating psychiatric disorders like depression, demonstrating the unique advantages and scientific value of Chinese patent medicines.
Comments